ILMN
ILMN clinical trials: ILLUMINA, INC.
Every trial on ClinicalTrials.gov where ILLUMINA, INC. is the lead sponsor or a listed collaborator, the trials it leads first, each labelled Lead or Collaborator. Phase, status and dates as registered.
- 26
- Trials linked
- 12
- As lead sponsor
- 14
- As collaborator
- 0
- Primary completions as lead sponsor, next 90 days
ILMN on the catalyst calendar · ILMN registry changes
- Primary completion Jan 31, 2024ActualNo phase registeredNCT04170985NeuroSeq: A Prospective Trial to Evaluate the Diagnostic Yield of Whole Genome Sequencing (WGS) in Adult NeurologyIllumina, Inc. · Neurologic DeficitsCompletedILMNLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 2024Sponsor estimateNo phase registeredNCT05656183CardioSeq: Impact of WGS in Individuals With CVDIllumina, Inc. · Cardiovascular DiseasesUnknown statusILMNLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 10, 2021ActualNo phase registeredNCT05049967iKnow: A Prospective Study to Evaluate the Use of Multi-omics in Multi-System, Early Onset DisordersIllumina, Inc. · Genetic DiseaseUnknown statusILMNLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Aug 30, 2019ActualNo phase registeredNCT03590678Collection of Whole Blood Specimens in Pregnant WomenIllumina, Inc. · Pregnancy RelatedCompletedILMNLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Nov 20, 2017ActualNo phase registeredNCT02808494Development of a Next Generation Sequencing (NGS) -Based Assay to Detect Preeclampsia Molecular MarkersIllumina, Inc. · PreeclampsiaCompletedILMNLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Feb 28, 2021ActualNo phase registeredNCT04561102Evaluation of the COVIDSeq Test in Nasal Swab and Saliva From a COVID-19 Asymptomatic PopulationIllumina, Inc. · SARS-CoV-2CompletedILMNLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Feb 28, 2021ActualNo phase registeredNCT04561089Evaluation of the COVIDSeq Test in Saliva Specimens From COVID-19 Asymptomatic Illumina PersonnelIllumina, Inc. · SARS-CoV-2CompletedILMNLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Apr 30, 2019ActualNo phase registeredNCT03290469NICUSeq: A Trial to Evaluate the Clinical Utility of Human Whole Genome Sequencing (WGS) Compared to Standard of Care in Acute Care...Illumina, Inc. · Rare DiseasesCompletedILMNLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 31, 2016ActualNo phase registeredNCT02268786Single Embryo TrAnsfeR of Euploid EmbryoIllumina, Inc. · InfertilityCompletedILMNLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 30, 2019ActualNo phase registeredNCT03620110A Study Collecting Blood Samples From Pregnant Women to Aid in the Development of a Noninvasive Prenatal TestIllumina, Inc. · PregnancyCompletedILMNLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Nov 2011ActualNo phase registeredNCT01426308Method Comparison and Clinical Specificity Study: Evaluation of the Infinium HD Cytogenetic Abnormality TestIllumina, Inc. · Post-natal CytogeneticsCompletedILMNLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Sep 2009ActualNo phase registeredNCT00959504Detection of Factor V Leiden G1691A and Factor II (Prothrombin) G20210A Point Mutations in DNAIllumina, Inc. · Detection and Genotyping of Factor V and Factor II Point MutationsCompletedILMNLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Aug 31, 2027Sponsor estimateNo phase registeredNCT05046444Solving Riddles Through SequencingMunich Leukemia Laboratory · LeukemiaRecruitingILMNCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Sep 2029Sponsor estimateNo phase registeredNCT05990179Genomic Uniformed-Screening Against Rare Disease In All NewbornsColumbia University · Early Onset Genetic Conditions With Near Complete PenetranceRecruitingILMNCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Nov 30, 2026Sponsor estimateNo phase registeredNCT03655223Early Check: Expanded Screening in NewbornsRTI International · Spinal Muscular AtrophyActive, not recruitingSRPTCollaboratorJNJCollaboratorILMNCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 2026Sponsor estimateNo phase registeredNCT06549218Genetic Newborn Screening for Rare Diseases Within the Screen4Care ProjectUniversity Hospital Freiburg · Newborn ScreeningRecruitingILMNCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Oct 18, 2027Sponsor estimateNo phase registeredNCT07201038Ultrafast Whole Genome Sequencing for Childhood CancerUniversity of Cambridge · Cancer ChildhoodRecruitingILMNCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jul 31, 2025ActualNo phase registeredNCT05372445Microbiome and Health Indicators in People With Obesity, Prediabetes and Type 2 Diabetes Undergoing a Lifestyle InterventionNational Council of Scientific and Technical Research, Argentina · Diabetes Mellitus, Type 2TerminatedILMNCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Sep 30, 2025Sponsor estimateNo phase registeredNCT05858268NeuralNET Cerebral Palsy Pilot StudyUniversity of Cambridge · Cerebral PalsyActive, not recruitingILMNCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 31, 2022ActualNo phase registeredNCT04935138Cell-free DNA Analysis of Chromosome Anomalies in Early Pregnancy LossQuest Diagnostics-Nichols Insitute · Early Pregnancy LossTerminatedILMNCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Sep 2011ActualNo phase registeredNCT02121873The Breast Duct: Pilot Study of Genomic Sequencing of Exfoliated Ductal Cells Obtained Through Endoscopy and LavageAtossa Therapeutics, Inc. · Breast CancerCompletedATOSLeadILMNCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jan 15, 2025Sponsor estimateNo phase registeredNCT05175651Prospective Electronic Polygenic Risk Study - Second PhaseScripps Translational Science Institute · Coronary Artery DiseaseNot yet recruitingILMNCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Nov 2023Sponsor estimateNo phase registeredNCT05072275Prospective Electronic Polygenic Risk StudyScripps Translational Science Institute · Coronary Artery DiseaseUnknown statusILMNCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion May 2023Sponsor estimateNo phase registeredNCT05058937A Study to Examine the Clinical Value of Comprehensive Genomic Profiling Performed by Belgian NGS Laboratories: a Belgian Precision...The Belgian Society of Medical Oncology · Solid TumorUnknown statusILMNCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jan 2014ActualNo phase registeredNCT01899079A Prospective Observational Study of Clinical Outcomes for the NanoString® Technologies Prosigna Gene Signature AssayNanoString Technologies, Inc. · Breast CancerCompletedILMNCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
Enrollment, interventions and the start and completion dates are locked on 25 rows here. Included with TrialScanner ($9.99 a month) and Signal8 Pro.
Unlock with TrialScannerShowing the first 25 trials. There are 1 more in this window; the full list is part of TrialScanner.
Unlock with TrialScanner